Region Genetic Association Analysis of Breast Cancer Patients With and Without Persistent Postsurgical Neuropathic Pain,” ...

The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and ExpositionIND application cleared for seventh ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

Immuno-oncology and cell-based treatments, which harness the body's own immune system to combat illnesses like cancer, have ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Plans to file an investigational new drug (IND) application for TSC-102-A0301, a TCR-T targeting CD45 on HLA-A*03:01, in the second half of 2025. Solid Tumor Program: TScan continues to expand the ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...